[PDF] Top 20 Biblioteca Histórica "Marqués de Valdecilla": memoria 2014
Has 10000 "Biblioteca Histórica "Marqués de Valdecilla": memoria 2014" found on our website. Below are the top 20 most common "Biblioteca Histórica "Marqués de Valdecilla": memoria 2014".
Mitochondria Determine Response to Anti-PD-1 Therapy: An Evidence-based Hypothesis
... death 1 (PD-1) axis are the most encouraging field of research in this context (4, ...objective response rate of Anti–PD(L)-1 therapy is about 20% for unknown ... See full document
175
Modulation of Mitochondrial Antiviral Signaling by Human Herpesvirus 8 Interferon Regulatory Factor 1
... this hypothesis, we first performed coimmunoprecipitations with total cell ex- tracts of resting and reactivated BCBL-1 ...with 1 g/ml of recombinant GFP or GFP-fused vIRF-1 expanded ... See full document
8
Drug response to PD-1/PD-L1 blockade: based on biomarkers
... before PD-1/PD-L1 blockade, delayed relapse after an initial objective tumor regression is a major barrier in the successful anti-PD-1/PD-L1 therapy due to some ... See full document
12
Alpha-fetoprotein (AFP) as tumor marker in a patient with urothelial cancer with exceptional response to anti-PD-1 therapy and an escape lesion mimic
... complete response to immune checkpoint blockade who developed an apparent escape ...To determine the nature of the lung lesion, the patient underwent resection and histopathological examination, which ... See full document
9
Multidimensional, quantitative assessment of PD-1/PD-L1 expression in patients with Merkel cell carcinoma and association with response to pembrolizumab
... that PD-L1 engagement of PD-1 receptors on CD4+ cells causes T-cell ...of anti-PD-1 [36, ...cytotoxic anti-tumor capabilities following immune checkpoint blockade [39, ... See full document
45
Mechanisms and microbial influences on CTLA-4 and PD-1-based immunotherapy in the treatment of cancer: a narrative review
... The recent discoveries that alterations of gut microbes improve the efficacy of ICB therapy has led to the idea of “oncomicrobiotics”. Oncomicrobiotics are drugs, com- pounds or microbes that are used to ... See full document
5
Nuclear IRF-1 expression as a mechanism to assess “Capability” to express PD-L1 and response to PD-1 therapy in metastatic melanoma
... file 1: Figure S3). Treated cases were then stratified into IRF-1- high and IRF-1-low cohorts using the lowest tertile as the IRF-1-low cohort (AQUA cutpoint = ...of therapy was ... See full document
6
Thoracic and cutaneous sarcoid-like reaction associated with anti-PD-1 therapy: longitudinal monitoring of PD-1 and PD-L1 expression after stopping treatment
... an anti-PD-1 mAb. The expression of PD-1 and its ligands, PD-L1 and PD-L2, was assessed by flow cytometry on peripheral blood mononuclear cells (PBMC) and compared to ... See full document
16
Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer
... an anti-tumor immune response. Enzalutamide therapy represents a more potent form of androgen suppression and may therefore be associated with previously under-appreciated immune modulatory ...showed ... See full document
8
Automated image analysis of NSCLC biopsies to predict response to anti-PD-L1 therapy
... objective response rate (ORR), disease control rate, duration of response, and progression-free survival (PFS) using Response Evalu- ation Criteria in Solid Tumors (RECIST) version ...or 1, ... See full document
52
Angiosarcoma treated successfully with anti-PD-1 therapy - a case report
... modality therapy including surgery and radiation appears to have a better outcome than each modality ...the PD-1 receptor or PD-L1 ligand has recently been shown to have activity in multiple ... See full document
11
CTLA4 methylation predicts response to anti–PD-1 and anti–CTLA-4 immunotherapy in melanoma patients
... In the non-ICB cohort, on average 84.75% of nuclei were tumor nuclei while mean methylation was only 43.1%. Accordingly, one or both CTLA4 alleles are unmethylated in a significant number of melano- ma cells. Several ... See full document
12
T cell Bim levels reflect responses to anti–PD-1 cancer therapy
... ipilimumab therapy and on BRAF inhibition therapy if BRAF mutant, age over 18 years, Eastern Cooperative Oncology Group performance status of 0 to 2, adequate organ function, and life expectancy ≥3 ... See full document
16
Combination anti–PD-1 and antiretroviral therapy provides therapeutic benefit against SIV
... inhibitor PD-1 blockade will have on HIV-1 tran- scription within latently infected CD4 + T cells during ...that PD-1 blockade may result in ... See full document
7
The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy
... of PD-1 in tumor- infiltrating T cells during tumor progression in GL261 glioma orthotopic murine glioma model, the survival time of which is around 30 days ...that PD-1 expression on both CD4 ... See full document
883
Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carcinoma
... modulate anti-tumor immune responses ...To determine whether the gut microbiome contributes to development of this disease, fecal microbiota transplantation (FMT) was performed in mice undergoing autoimmune ... See full document
78
Wnt/beta-catenin pathway: modulating anticancer immune response
... Wnt/β-catenin signaling pathway is required for self- renewal of CSCs. Yeung et al. demonstrated that β- catenin was activated during development of mixed- lineage leukemia (MLL) CSCs. Suppression of β-catenin reversed ... See full document
88
Rescue therapy for patients with anti-PD-1-refractory Merkel cell carcinoma: a multicenter, retrospective case series
... testing PD-1-pathway blockers in patients with advanced ...cases, anti-tumor responses to these therapies have been profound and dur- ...effective therapy for patients whose disease is ... See full document
12
Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade
... clinical evidence of, potential long-term anti-tumor immunity after administration of anti-PD-1, an immune checkpoint ...durable anti-tumor responses in patients with multiple ... See full document
15
Efficacy of metformin in combination with immune checkpoint inhibitors (anti-PD-1/anti-CTLA-4) in metastatic malignant melanoma
... ment response due to the emergence of resistance, against B-RAF inhibitors, for instance ...clinical response result in significantly lower overall survival (OS) and life expect- ancy ... See full document
6
Related subjects